Robuta

https://scholars.uky.edu/en/projects/comparison-of-alemtuzumab-and-rebif-efficacy-in-multiple-sclerosi-3/ Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis: CAMMS323 and 324 - University... https://pubmed.ncbi.nlm.nih.gov/32382083/ Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the... PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in... https://adisinsight.springer.com/drugsafety/803286775?error=cookies_not_supported&code=51d91446-7ddf-4926-a662-704b5d7586f3 Alemtuzumab - AdisInsight In a single centre observational study, two women [ages not stated] were described, who developed cervical dysplasia following treatment with alemtuzumab alemtuzumabadisinsight https://pure.psu.edu/en/publications/alemtuzumab-campath-1h-experience-in-kidney-transplantation-what-/ Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current... what we have learnedkidney transplantation https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb9341 Alemtuzumab (Multiple Sclerosis) - Injection multiple sclerosisalemtuzumabinjection https://pubmed.ncbi.nlm.nih.gov/30645645/ Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with... Alemtuzumab induction therapy followed by reduced maintenance immunosuppression is associated with a better kidney function compared to no induction and ATG.... alemtuzumabinductioncombinedreducedmaintenance https://www.lemtrada.com/ Relapsing Multiple Sclerosis (MS) Treatment | LEMTRADA® (alemtuzumab) IV 12mg Explore LEMTRADA® (alemtuzumab), an infusion therapy for relapsing forms of multiple sclerosis (MS). Learn about dosing, treatment schedules and more. See... relapsing multiple sclerosismstreatmentalemtuzumabiv https://ibme.ox.ac.uk/publication/fractionation-of-bovine-serum-albumin-and-monoclonal-antibody-alemtuzumab-using-carrier-phase-ultrafiltration/ Fractionation of bovine serum albumin and monoclonal antibody alemtuzumab using carrier phase... bovine serum albumin https://pubmed.ncbi.nlm.nih.gov/33476880/ Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years Alemtuzumab had greater efficacy than SC IFNB-1a over 2 years across comparable age groups, with no significant differences between alemtuzumab-treated age... https://adisinsight.springer.com/drugsafety/803089772?error=cookies_not_supported&code=5ee14a75-e0dc-4709-85fe-841c2da0f174 Alemtuzumab/antithymocyte globulin - AdisInsight A 58-year-old woman developed adenoviral encephalomyeloradiculitis following treatment with antithymocyte globulin and alemtuzumab. She subsequently died.The alemtuzumabadisinsight https://adisinsight.springer.com/drugsafety/803133671?error=cookies_not_supported&code=8d7525d6-f287-470d-ad9e-2d815811b707 Alemtuzumab - AdisInsight A 52-year-old man developed Mycobacterium chelonae osteomyelitis following treatment with alemtuzumab.The man presented with a 6-week history of right big toe alemtuzumabadisinsight https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-into-alemtuzumab-and-methylprednisolone-for-people-with-chronic-lymphocytic-leukaemia-with-a-p53-gene-defect A trial looking into alemtuzumab and methylprednisolone for people with chronic lymphocytic... This trial was looking to see how well the combination of alemtuzumab (Mabcampath) and methylprednisolone worked for chronic lymphocytic leukaemia. https://scholars.uky.edu/en/publications/reader-response-alemtuzumab-care-ms-ii-5-year-follow-up-efficacy-/ Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings - University... https://pubmed.ncbi.nlm.nih.gov/23122652/ Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting... Genzyme (Sanofi) and Bayer Schering Pharma. https://fis.tu-dresden.de/portal/de/publications/proportion-of-alemtuzumabtreated-patients-converting-from-relapsingremitting-multiple-sclerosis-to-secondary-progressive-multiple-sclerosis-over-6-years(b100b213-cf22-4d7f-bfe9-b622db43f90e).html Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis... proportionalemtuzumabtreatedpatients https://adisinsight.springer.com/drugsafety/803114732?error=cookies_not_supported&code=cccf4bc8-7cca-4b08-911a-0f40a40632f8 Alemtuzumab - AdisInsight A man [age not stated] developed cytokine release syndrome (CRS) after starting alemtuzumab [dosage and route not stated] for T-prolymphocytic leukaemia.Within alemtuzumabadisinsight https://adisinsight.springer.com/drugsafety/803424609?error=cookies_not_supported&code=b0a6cee0-86d8-4bac-a4af-ad8c97f2a831 Alemtuzumab - AdisInsight In a study of 23 patients (treated with alemtuzumab from 2015 to 2018), 3 patients [ages and sexes not stated] were described, who developed herpes zoster alemtuzumabadisinsight https://research.rug.nl/en/publications/treatment-of-steroid-resistant-acute-renal-allograft-rejection-wi/ Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab - the University of... https://eprints.ncl.ac.uk/231427 Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort:... https://brainandmind.weill.cornell.edu/immediate-transient-thrombocytopenia-time-alemtuzumab-infusion-multiple-sclerosis Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. |... at the time https://adisinsight.springer.com/drugsafety/803384242?error=cookies_not_supported&code=59043df3-5998-44de-9e06-a55bb365eac8 Alemtuzumab - AdisInsight In a retrospective study of patients treated with alemtuzumab between July 2014 and May 2017, an adult female patient [age at reaction onset not stated] was alemtuzumabadisinsight https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1509987/full Frontiers | The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple... Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and ... https://research.birmingham.ac.uk/en/publications/paraproteinaemia-after-allo-sct-association-with-alemtuzumab-base/ Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV... allosctassociation https://pubmed.ncbi.nlm.nih.gov/18223357/ A fatal case of alemtuzumab-associated interstitial pneumonitis Alemtuzumab is a humanized monoclonal antibody primarily used in refractory chronic lymphocytic leukemia. Although bronchospasm and infectious pneumonia are... fatalcasealemtuzumabassociatedinterstitial https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00253/full Frontiers | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS... Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognit... https://experts.umn.edu/en/publications/outcomes-associated-with-steroid-avoidance-and-alemtuzumab-among-/ Outcomes associated with steroid avoidance and alemtuzumab among kidney transplant recipients -... associated withkidney transplantoutcomessteroidavoidance https://experts.umn.edu/en/publications/outcomes-associated-with-steroid-avoidance-and-alemtuzumab-among-/fingerprints/ Outcomes associated with steroid avoidance and alemtuzumab among kidney transplant recipients -... associated withkidney transplantoutcomessteroidavoidance https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6236b0bc-82e9-4447-9a78-f57d94770269&audience=professional DailyMed - LEMTRADA- alemtuzumab injection, solution, concentrate injection solutiondailymedlemtradaalemtuzumabconcentrate https://scholars.uky.edu/es/publications/reader-response-alemtuzumab-care-ms-ii-5-year-follow-up-efficacy-/fingerprints/ Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings - Huella - https://adisinsight.springer.com/drugsafety/803875710?error=cookies_not_supported&code=d9b5819d-cf95-4f9c-ba35-a42c7b529e68 Alemtuzumab - AdisInsight In a study, involving 11 patients with renal transplant, a patient [age and sex not stated] was described who developed wound infection during off label therapy alemtuzumabadisinsight